March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Dexamethasone Intravitreal Implants For Retinal Vein Occlusion In A Clinical Setting
Author Affiliations & Notes
  • Valerie Krivosic
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Sylvain Michee
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Benedicte Dupas
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Sebastien Bruno
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Alain Gaudric
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Pascale Massin
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Ramin Tadayoni
    Ophthalmology, Lariboisiere Hospital, Paris, France
  • Footnotes
    Commercial Relationships  Valerie Krivosic, None; Sylvain Michee, None; Benedicte Dupas, None; Sebastien Bruno, None; Alain Gaudric, None; Pascale Massin, None; Ramin Tadayoni, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 924. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valerie Krivosic, Sylvain Michee, Benedicte Dupas, Sebastien Bruno, Alain Gaudric, Pascale Massin, Ramin Tadayoni; Dexamethasone Intravitreal Implants For Retinal Vein Occlusion In A Clinical Setting. Invest. Ophthalmol. Vis. Sci. 2012;53(14):924.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate efficacy and side effects of dexamethasone intravitreal implant in a clinical setting.

Methods: : Retrospective study including consecutive patients treated for retinal vein occlusion (RVO) with a dexamethasone intravitreal implant (ozurdex ®) in our department and with a follow-up > 2 months. 41 patients were included. Indication was in all cases cystic macular edema associated with 21 cases of central retinal vein occlusion and 20 cases of branch retinal vein occlusion. Median age was 66.37 yo (range: 29 to 90). Among patients, 61.9% were male and 38.1% were female. The follow up was 2-9 months. Evaluation criteria were: visual acuity before and 2 months after injection, side effects during follow-up, anatomical improvement on OCT, numbers of injections, and time between injections.

Results: : The Median visual acuity improved from 0.25 (0.05 to 0.5) before injection to 0.38 (0.05 to 0.8) at the end of the follow up. Macular edema improved (OCT mapping) in 80.55% of eyes. Among the 28 patients who had a follow-up > 6 months (range: 6-9 months) 10 patients (35.71%) had a recurrence of their edema needing a second injection. The delay between the 2 injections in these 10 patients was 5.45 months (3 to 8 months). Side effects were reported in 44.44% of patients: 36.11% presented an hypertonia needing medication prescription, among phakic patients 12.9% presented an early cataract. One patient had a retinal detachment (2.44%).

Conclusions: : In this study, dexamethasone intravitreal implant improved vision and decreased edema due to retinal vein occlusions. Two third (2/3) of patients followed-up > 6 months did not need a second injection during their follow-up (6 to 9 months). Side effects were above all ocular hypertonia in 36.11% of patients but also cataract. In this series one patient presented a retinal detachment.In our clinical setting dexamethasone intravitreal implant was effective for the treatment for macular edema due to RVO and the main complications were hypertonia in nearly 1/3 of patients and cataract.

Keywords: vascular occlusion/vascular occlusive disease • edema • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.